Drug Profile

Nelitolimod - TriSalus Life Sciences

Alternative Names: ISS-ODN SD-101; SD-101; SD101-Dynavax

Latest Information Update: 11 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dynavax Technologies
Developer Bristol-Myers Squibb; Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; TriSalus Life Sciences; University of California, Davis
Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
Mechanism of Action Toll-like receptor 9 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Prostate cancer
Phase I/II B-cell lymphoma; Cholangiocarcinoma; Follicular lymphoma; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma
Phase I Pancreatic cancer; Uveal melanoma
Preclinical Colorectal cancer
No development reported Haematological malignancies; Hepatitis C; Solid tumours

31 Mar 2025 University of California in collaboration with Merck Sharp & Dohme and TriSalus Life Sciences completes a hpase-II clinical trials in Prostate cancer (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Treatment-naive) in USA (Intratumoural) (NCT03007732)
27 Mar 2025 TriSalus Life Sciences completes enrollment in a phase-I clinical trials in Pancreatic cancer (Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy, Monotherapy) in USA (Intratumoural, Infusion) (NCT05607953)
03 Jan 2025 Phase-I clinical trials in Liver cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, First-line therapy) in USA (Intrahepatic) (NCT06710223)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com